Objective Human adult articular cartilage (AC) has little capacity for repair, and joint surface injuries often result in osteoarthritis (OA), characterised by loss of matrix, hypertrophy and chondrocyte apoptosis. Inflammation mediated by interleukin (IL)-6 family cytokines has been identified as a critical driver of proarthritic changes in mouse and human joints, resulting in a feed-forward process driving expression of matrix degrading enzymes and IL-6 itself. Here we show that signalling through glycoprotein 130 (gp130), the common receptor for IL-6 family cytokines, can have both context-specific and cytokine-specific effects on articular chondrocytes and that a small molecule gp130 modulator can bias signalling towards anti-inflammatory and antidegenerative outputs.
Methods High throughput screening of 170 000 compounds identified a small molecule gp130 modulator termed regulator of cartilage growth and differentiation (RCGD 423) that promotes atypical homodimeric signalling in the absence of cytokine ligands, driving transient increases in MYC and pSTAT3 while suppressing oncostatin M- and IL-6-mediated activation of ERK and NF-κB via direct competition for gp130 occupancy.
Results This small molecule increased proliferation while reducing apoptosis and hypertrophic responses in adult chondrocytes in vitro. In a rat partial meniscectomy model, RCGD 423 greatly reduced chondrocyte hypertrophy, loss and degeneration while increasing chondrocyte proliferation beyond that observed in response to injury. Moreover, RCGD 423 improved cartilage healing in a rat full-thickness osteochondral defect model, increasing proliferation of mesenchymal cells in the defect and also inhibiting breakdown of cartilage matrix in de novo generated cartilage.
Conclusion These results identify a novel strategy for AC remediation via small molecule-mediated modulation of gp130 signalling.
- disease activity
Statistics from Altmetric.com
RS, BVH and JB contributed equally.
Handling editor Tore K Kvien
Contributors RS, BVH, JB and DE designed experiments; RS, BVH, JB, SL, YY, MS, NWB, SL, AC, CEF, MPA, LW, GBF, KV, NQL and DE conducted experiments; VJ, AN, FAP, CTV, LW and PB provided expertise and/or reagents; BVH and DE wrote the manuscript, all authors reviewed it.
Funding This work is supported by NIH grant K01AR061415, Department of Defense grant W81XWH-13-1-0465, California Institute for Regenerative Medicine grant RB5-07230, a USC Stevens Technology Advancement Grants award and a Wright Foundation award (all to DE) as well as a postdoctoral scholarship from Fundação de Amparoà Pesquisa do Estado de São Paulo E FAPESP (grant# 2015/08952E6) to CEF.
Competing interests DE, BVH and VJ are inventors onPCT/US16/20126. DE and BVH are cofounders and shareholdersof CarthroniX.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Primer sequences are available upon request; please contact the corresponding authors.
Correction notice This article has been corrected since it published Online First. The affiliation for Mohammad Parvez Alam has been corrected.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.